Hard to Treat Diseases (HTDS) Collagenna Skin Care Products Expands in Europe

OTTAWA, March 9 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) announces that Collagenna Skin care Products has entered into an exclusive distribution agreement with Alphaderm Body and Wellness (www.alphaderm.ch) for Switzerland.

Alphaderm Body and Wellness, a small Swiss Company, developed a line of Body Products with focus on cellulite reduction. Alphaderm sells their line in specialized skin care clinics throughout Switzerland. The company's flagship product is the 'Alphaderm Body Former Anti-cellulite Cream'.

Irene Grimm, founder and CEO of Alphaderm Body & Wellness states, said, " We have been looking for a facial skin care line and I heard about the Collagenna Skin Care Line. We tried the products and were very impressed by them. We know that our client base of about 500 clinics will want to carry this line, and it will allow us to build up our business and expand very rapidly. We have several marketing activities planned and we want to officially introduce the line to the Swiss Industry later in April, 2010. Our initial order of last week sold out in 2 days, so we are very excited."

CEO Michael Arnkvarn stated, "It is our plan to expand further into the European Markets. We have a presence in Scandinavia and now Switzerland. We plan to open at least 2 more countries this year, and we expect Alphaderm Body and Wellness to be an integral partner in this expansion."

The company reminds our shareholders and followers to monitor PinkSheets.com Filing Section and also our IR company web site section "NEWS AND FILINGS" TAB. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the http://www.stockbasher.com/ web site. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and other media that provide safe refuge to these individuals and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases